elevate plasma calcium by promoting bone resorption and decreasing calcium ria, Australia. excretion. Assays for plasma PTH-rP fail to detect protein convincingly in normal plasma, but measurable levels have been found in up to 100% of patients with HHM, in 75% of patients with breast carcinoma met
Parathyroid hormone-related protein and hypercalcemia in pancreatic neuro-endocrine tumors
β Scribed by R. Rizzoli; A. P. Sappino; J. -P. Bonjour
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- French
- Weight
- 682 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
We investigated the possible involvement of parathyroid hormone-related protein (PTHrP) in 2 cases of metastatic pancreatic neuro-endocrine tumors associated with severe hypercalcemia. Both patients displayed biochemical alterations in renal tubular reabsorption of calcium and phosphate, as well as in urinary CAMP excretion, similar to those encountered in primary hyperparathyroidism, although plasma levels of parathyroid hormone were within the normal range. Tumor protein extracts stimulated CAMP production, which was inhibited by the PTH-antagonist (&I6 Nle, 34 Tyr)bPTH-(3-34)amide, in the PTH-responsive osteoblastic cell line UMR-106. Northern blot analysis of tumor extracts revealed the presence of PTHrP mRNA transcripts, while PTH mRNA was undetectable. In contrast, neither PTHrP mRNA(s) nor CAMP-stimulating activity was detectable in other neuroendocrine tumors not accompanied by hypercalcemia. These results demonstrate that certain pancreatic neuroendocrine tumors associated with hypercalcemia can synthesize and release PTHrP.
π SIMILAR VOLUMES
## BACKGROUND. Although lung carcinoma is the most common cause of tumorinduced hypercalcemia (TIH), the precise incidence of TIH remains obscure. Furthermore, the role of parathyroid hormone-related protein (PTHrP) has not been clearly elucidated.
## Abstract This is a report of a 7βmonthβold infant with malignant rhabdoid tumor of the kidney (RTK). The patient (pt) demonstrated clinical and biochemical evidence of humoral hypercalcemia of malignancy (HHM). The hypercalcemia responded promptly to calcitonin treatment and tumor removal. Despi